ReviewNeurology and therapy2014
Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain.
Review in Neurology and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2016Pooled it
- Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Concordance between Centiloid Quantification and Visual Interpretation of Amyloid PET Scans across the Alzheimer Disease Continuum.AJNR. American journal of neuroradiology · 2025Article
- Advancing Amyloid Aggregation Research: A Focus on Innovative Therapies, Molecular Modeling and Nano-Delivery Systems in Alzheimer's Disease.Current drug targets · 2025Review
- Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Two decades of [American journal of nuclear medicine and molecular imaging · 2024Review
- Advances in Understanding and Managing Alzheimer's Disease: From Pathophysiology to Innovative Therapeutic Strategies.Current drug targets · 2024Review
- Does statin use affect amyloid beta deposition and brain metabolism?CNS neuroscience & therapeutics · 2023Article
- Linguistic, visuospatial, and kinematic writing characteristics in cognitively impaired patients with beta-amyloid deposition.Frontiers in aging neuroscience · 2023Article
- Divalent 2-(4-Hydroxyphenyl)benzothiazole Bifunctional Chelators forInorganic chemistry · 2022Article
- Amyloid Beta in Aging and Alzheimer's Disease.International journal of molecular sciences · 2022Review
- Dynamic Amyloid PET: Relationships toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Molecular and cellular pathophysiology of preclinical Alzheimer's disease.Behavioural brain research · 2016Review
- Treatment of Mild Cognitive Impairment.Current treatment options in neurology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting the elderly. Current clinical diagnostic tools are often ineffective in accurately diagnosing AD. However, new advances in diagnostic imaging, particularly positron emission tomography (PET) amyloid imaging, have shown increased sensitivity and specificity, as well as high inter-reader agreement. The most commonly studied tracer, PiB-C11, has shown high affinity binding to amyloid, but is limited in its use outside of research due to its short half-life. Instead, development of other PET ligands with increased half-life, such as fluorine-18-labeled ((18)F) tracers, allows for more widespread use of PET in clinical settings. In particular, recent phase II and III trials of (18)F-florbetaben have demonstrated the high accuracy of this PET tracer in identifying amyloid accumulation. This paper will examine the techniques of amyloid imaging, focusing particularly on the recently approved (18)F-florbetaben.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.